ctrl K

Watchlist Price Alert

RenovoRx Inc. (RNXT)

NASDAQ: RNXT · Real-Time Price · USD

1.40

0.01 (0.72%)

At close: Jun 05, 2025, 3:59 PM

0.72% (1D)

Bid	1.25
Market Cap	51.02M
Revenue (ttm)	240K
Net Income (ttm)	-10.16M
EPS (ttm)	-0.41
PE Ratio (ttm)	-3.4
Forward PE	-4.21
Analyst	Strong Buy

Ask	1.47
Volume	192,134
Avg. Volume (20D)	141,898
Open	1.41
Previous Close	1.39
Day's Range	1.36 - 1.42
52-Week Range	0.75 - 1.69
Beta	1.12

About RNXT

undefined

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RNXT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RNXT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

-20.55%

RenovoRx shares are trading lower after the compan... Unlock content with Pro Subscription

3 months ago

-2.01%

RenovoRx shares are trading lower after the company announced a proposed public offering.

News

news image

3 weeks ago · seekingalpha.com

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

RenovoRx, Inc. (NASDAQ:RNXT ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Valter Pinto - IR Ramtin Agah - Founder and Chief Medical Officer Shaun Bagai - CEO Ronald K...

news image

3 weeks ago · zacks.com

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

news image

3 weeks ago · businesswire.com

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renov...

news image

3 weeks ago · businesswire.com

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renov...

news image

1 month ago · businesswire.com

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renov...

news image

1 month ago · businesswire.com

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renov...

news image

1 month ago · businesswire.com

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renov...

news image

1 month ago · businesswire.com

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renov...

news image

2 months ago · businesswire.com

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renov...

news image

2 months ago · businesswire.com

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renov...

Load More News